Phar Vision Advisers, LLC Aquestive Therapeutics, Inc. Transaction History
Phar Vision Advisers, LLC
- $178 Billion
- Q3 2025
A detailed history of Phar Vision Advisers, LLC transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Phar Vision Advisers, LLC holds 46,450 shares of AQST stock, worth $250,365. This represents 0.15% of its overall portfolio holdings.
Number of Shares
46,450Holding current value
$250,365% of portfolio
0.15%Shares
1 transactions
Others Institutions Holding AQST
# of Institutions
162Shares Held
65.9MCall Options Held
794KPut Options Held
457K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$52.9 Million100.0% of portfolio
-
Rtw Investments, LP New York, NY6.25MShares$33.7 Million0.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.66MShares$30.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$29.4 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.76MShares$20.3 Million0.05% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $288M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...